Authors

Op-Ed: Cannabis Policy Needs Pharmacists

Canada’s experience demonstrates the risks of sidelining pharmacy in medical cannabis policy.

FGFR Inhibitors for Treatment of Primary CNS Tumors

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

Reduced POMP Dosing Shows Comparable Efficacy in ALL Maintenance

Arefa Bacchus, PharmD, shared key insights about the use of POMP therapy in patients with acute lymphoblastic leukemia (ALL).

Optimizing Biomarker Testing in NSCLC to Expand Targeted Treatment Options

Pharmacists can help standardize biomarker testing and improve access to targeted therapies in non–small cell lung cancer.

Opinion: To Succeed, Direct-to-Patient Drug Sales Will Require Better Technology

High-Risk, Low-Benefit Treatments for Chronic Low Back Pain Demand Reevaluation

In an interview with Pharmacy Times, Caitlin Jones, PhD, discusses why high-risk, low-benefit treatments for chronic low back pain require greater scrutiny.

Sibeprenlimab-szsi for Primary IgA Nephropathy: A New Drug Review

Sibeprenlimab, a new APRIL blocker, cuts proteinuria in IgA nephropathy.

What the Metrics Don't Measure

Pharmacists quietly prevent medication harm, ease discharge chaos, and manage rising health care strain through unseen cognitive work.

Specialty Pharmacy Technicians in Oncology Transitions of Care: An Untapped Workforce Resource

Specialty pharmacy technicians address barriers in oral anticancer therapy and transitions of care through improved care coordination and therapy access.

Respiratory Syncytial Virus in Older Adults: Research Insights and Recommendations

Although RSV has long been associated with infants and young children, research demonstrates that it is also a significant health risk for adults over the age of 60.

Revolutionizing Treatment with Bispecific Therapies: Navigating the Challenges Ahead

By decade’s end, approval of additional bispecifics is expected for hematological malignancies, solid tumors, and non-oncology conditions such as inflammatory, autoimmune, neurodegenerative and vascular diseases, and ocular disorders and infections.

Pharmacy Fellowship Survival Guide: Work-Life Balance, Wellness, and Time Management Strategies

How to thrive professionally and personally during pharmacy fellowship

Preserving Access to Preventive Care Amid a Changing Health Care Environment

Community pharmacists are crucial in Increasing immunization rates, addressing access barriers, and supporting evidence-based immunization guidance.

A Hospital’s Outpatient Pharmacies Attempt to Reduce DIR Fees Using Performance Reports

This quality improvement initiative demonstrates that pharmacies were unable to use performance reports provided by the payer to improve performance scores and decrease direct and indirect remuneration (DIR) fees.

Re-adding EXPAREL to Formulary: The Pharmacist Perspective

This article is sponsored by Pacira Pharmaceuticals, Inc.

From Type 1 to Type 2 and Beyond: Navigating the Landscape of Diabetes

Explore the rising prevalence of diabetes in the US, its various types, and the critical role pharmacists play in patient care.

The Evolving Role of Pharmacovigilance in Digital Therapeutics

Digital therapeutics (DTx), a novel evidence-based software approach, is revolutionizing health care by delivering personalized treatments. Pharmacovigilance ensures DTx safety but faces challenges such as data privacy and standardization.

FDA and Novo Nordisk Warned of GLP-1 Telehealth Compounding Takedown. What’s Next?

The FDA ramps up action on compounded GLP‑1 weight‑loss drugs, targeting telehealth ads as Novo Nordisk sues Hims & Hers and regulators hint at seizures.

Pharmacy Fellowship Survival Guide: Work-Life Balance, Wellness, and Time Management Strategies

How to thrive professionally and personally during pharmacy fellowship

Exploring the Antidepressant Potential of GLP-1 Receptor Agonists

GLP-1 receptor agonists show promise in alleviating depressive symptoms in patients with type 2 diabetes, offering a potential dual benefit in treatment.

Emerging BCMA-Directed Therapies in Multiple Myeloma: Bispecific Antibodies and CAR T-Cell Therapies

Here is an updated overview of the role of BCMA-directed therapies following the 2024 ASCO Annual Meeting and EHA Congress.

The Gold Standard: Why Dual-Credentialing Is the Backbone of Pharmacy Safety

PTCB credentialing elevates pharmacy technicians’ safety and career commitment, boosts patient trust, and enables efficient delegation—helping reduce medication errors in modern pharmacies.

Evaluating Clinical Safety of BTK Inhibitors: Cardiovascular Events and Drug-Drug Interactions

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

Community Pharmacy Credentialing: Why Part D Coverage No Longer Guarantees Part B Payment

As pharmacies expand into offering immunizations and other clinical services, the rules for the Part B medical side have moved away from the traditional pharmacy side.

Improve Skin Health Through Student Pharmacist Education

Student pharmacists boost dermatology literacy in underserved communities, improving sunscreen habits, skin cancer warning recognition, and practical skin health self-care.

ADA 2026: Earlier GLP-1 and SGLT-2 Use Recommended From Diabetes Diagnosis, Expert Says

John Buse, MD, PhD, breaks down the 2026 American Diabetes Association (ADA) hyperglycemia guidance update, including earlier glucagon-like peptide-1 (GLP-1) receptor agonist and sodium-glucose cotransporter 2 (SGLT-2) inhibitor use and a broader holistic care framework.

Some Pharmacists Find Better Balance in New Zealand

Some pharmacists are exploring the possibilities of moving to New Zealand for better work/life balance.

Advancing Precision Oncology Through Pharmacy-Led Innovation

Precision oncology has shifted, yet pharmacists’ roles remain underutilized.

Medetomidine in the Illicit Drug Supply: What Pharmacists Need to Know About "Rhino Tranq" and Naloxone-Resistant Overdoses

As medetomidine rapidly displaces xylazine as a fentanyl adulterant, pharmacists must recognize its distinct toxidrome, understand why naloxone alone is insufficient, and support updated harm reduction strategies in an increasingly complex overdose landscape.